;PMID: 8641983
;source_file_517.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:44..256] = [t:44..256]
;2)section:[e:260..364] = [t:260..364]
;3)section:[e:368..456] = [t:368..456]
;4)sentence:[e:460..674] = [t:460..674]
;5)sentence:[e:675..826] = [t:675..826]
;6)sentence:[e:827..909] = [t:827..909]
;7)sentence:[e:910..1054] = [t:910..1054]
;8)sentence:[e:1055..1216] = [t:1055..1216]
;9)sentence:[e:1217..1363] = [t:1217..1363]
;10)sentence:[e:1364..1583] = [t:1364..1583]
;11)section:[e:1587..1631] = [t:1587..1631]

;section 0 Span:0..39
;Jpn J Cancer Res  1996 May;87(5):466-74
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..16] Res)
        (CC:[18..22] 1996) (NNP:[23..26] May) (CD:[26..30] ;87-LRB-)
        (CD:[30..31] 5) (-RRB-:[31..32] -RRB-) (CD:[32..36] :466)
        (IN:[36..37] -) (CD:[37..39] 74)))

;sentence 1 Span:44..256
;Detection of K-ras point mutations at codon 12 in pancreatic juice for the 
;diagnosis of pancreatic cancer by hybridization protection assay: a simple 
;method for the determination of the types of point mutation.
;[57..62]:gene-rna:"K-ras"
;[63..78]:variation-type:"point mutations"
;[82..90]:variation-location:"codon 12"
;[133..150]:malignancy:"pancreatic cancer"
;[241..255]:variation-type:"point mutation"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[44..53] Detection))
      (PP (IN:[54..56] of)
        (NP (NN:[57..62] K-ras)
           (NN:[63..68] point) (NNS:[69..78] mutations)))
      (PP-LOC (IN:[79..81] at)
        (NP (NN:[82..87] codon) (CD:[88..90] 12)))
      (PP-LOC (IN:[91..93] in)
        (NP (JJ:[94..104] pancreatic) (NN:[105..110] juice)))
      (PP (IN:[111..114] for)
        (NP
          (NP (DT:[115..118] the) (NN:[120..129] diagnosis))
          (PP (IN:[130..132] of)
            (NP (JJ:[133..143] pancreatic) (NN:[144..150] cancer)))
          (PP-MNR (IN:[151..153] by)
            (NP (NN:[154..167] hybridization) (NN:[168..178] protection)
                (NN:[179..184] assay))))))
    (::[184..185] :)
    (NP
      (NP (DT:[186..187] a) (JJ:[188..194] simple) (NN:[196..202] method))
      (PP (IN:[203..206] for)
        (NP
          (NP (DT:[207..210] the) (NN:[211..224] determination))
          (PP (IN:[225..227] of)
            (NP
              (NP (DT:[228..231] the) (NNS:[232..237] types))
              (PP (IN:[238..240] of)
                (NP (NN:[241..246] point) (NN:[247..255] mutation))))))))
    (.:[255..256] .)))

;section 2 Span:260..364
;Watanabe H, Miyagi C, Yamaguchi Y, Satomura Y, Ohta H, Motoo Y, Okai T, 
;Yoshimura T, Tsuji Y, Sawabu N.
(SEC
  (FRAG (NNP:[260..268] Watanabe) (NNP:[269..270] H) (,:[270..271] ,)
        (NNP:[272..278] Miyagi) (NNP:[279..280] C) (,:[280..281] ,)
        (NNP:[282..291] Yamaguchi) (NNP:[292..293] Y) (,:[293..294] ,)
        (NNP:[295..303] Satomura) (NNP:[304..305] Y) (,:[305..306] ,)
        (NNP:[307..311] Ohta) (NNP:[312..313] H) (,:[313..314] ,)
        (NNP:[315..320] Motoo) (NNP:[321..322] Y) (VBD:[322..323] ,)
        (NNP:[324..328] Okai) (NNP:[329..330] T) (VBD:[330..331] ,)
        (NNP:[333..342] Yoshimura) (NNP:[343..344] T) (,:[344..345] ,)
        (NNP:[346..351] Tsuji) (NNP:[352..353] Y) (,:[353..354] ,)
        (NNP:[355..361] Sawabu) (NNP:[362..364] N.)))

;section 3 Span:368..456
;Department of Internal Medicine, Cancer Research Institute, Kanazawa
;University,  Japan.
(SEC
  (FRAG (NNP:[368..378] Department) (IN:[379..381] of) (NNP:[382..390] Internal)
        (NNP:[391..399] Medicine) (,:[399..400] ,) (NNP:[401..407] Cancer)
        (NNP:[408..416] Research) (NNP:[417..426] Institute) (,:[426..427] ,)
        (NNP:[428..436] Kanazawa) (NNP:[437..447] University) (,:[447..448] ,)
        (NNP:[450..455] Japan) (.:[455..456] .)))

;sentence 4 Span:460..674
;The present study was undertaken to detect K-ras oncogene point mutations at 
;codon 12 in pure pancreatic juice (PPJ) by the hybridization protection assay
; (HPA) method for the diagnosis of pancreatic cancer (PC).
;[503..508]:gene-rna:"K-ras"
;[518..533]:variation-type:"point mutations"
;[538..546]:variation-location:"codon 12"
;[651..668]:malignancy:"pancreatic cancer"
;[670..672]:malignancy:"PC"
(SENT
  (S
    (NP-SBJ-1 (DT:[460..463] The) (JJ:[464..471] present) (NN:[472..477] study))
    (VP (VBD:[478..481] was)
      (VP (VBN:[482..492] undertaken)
        (NP-1 (-NONE-:[492..492] *))
        (S-PRP
          (NP-SBJ (-NONE-:[492..492] *))
          (VP (TO:[493..495] to) (VB:[496..502] detect)
            (NP
              (NML (NN:[503..508] K-ras) (NN:[509..517] oncogene))
               (NN:[518..523] point) (NNS:[524..533] mutations))
            (PP-LOC (IN:[534..536] at)
              (NP (NN:[538..543] codon) (CD:[544..546] 12)))
            (PP-LOC (IN:[547..549] in)
              (NP
                (NP (JJ:[550..554] pure) (JJ:[555..565] pancreatic)
                    (NN:[566..571] juice))
                (NP (-LRB-:[572..573] -LRB-) (NN:[573..576] PPJ)
                    (-RRB-:[576..577] -RRB-))))
            (PP-MNR (IN:[578..580] by)
              (NP
                (NP (DT:[581..584] the)
                  (NML
                    (NML (NN:[585..598] hybridization)
                         (NN:[599..609] protection) (NN:[610..615] assay))
                    (NML (-LRB-:[617..618] -LRB-) (NN:[618..621] HPA)
                         (-RRB-:[621..622] -RRB-)))
                  (NN:[623..629] method))
                (PP (IN:[630..633] for)
                  (NP
                    (NP (DT:[634..637] the) (NN:[638..647] diagnosis))
                    (PP (IN:[648..650] of)
                      (NP
                        (NP (JJ:[651..661] pancreatic) (NN:[662..668] cancer))
                        (NP (-LRB-:[669..670] -LRB-) (NN:[670..672] PC)
                            (-RRB-:[672..673] -RRB-))))))))))))
    (.:[673..674] .)))

;sentence 5 Span:675..826
;This assay can be  carried out within 30 min and can determine not only the
;presence of a mutation,  but also the mutational type of K-ras at codon 12.
;[765..773]:variation-event:"mutation"
;[808..813]:gene-rna:"K-ras"
;[817..825]:variation-location:"codon 12"
(SENT
  (S
    (NP-SBJ-1 (DT:[675..679] This) (NN:[680..685] assay))
    (VP
      (VP (MD:[686..689] can)
        (VP (VB:[690..692] be)
          (VP (VBN:[694..701] carried)
            (NP-1 (-NONE-:[701..701] *))
            (PRT (RP:[702..705] out))
            (PP-TMP (IN:[706..712] within)
              (NP (CD:[713..715] 30) (NN:[716..719] min))))))
      (CC:[720..723] and)
      (VP (MD:[724..727] can)
        (VP (VB:[728..737] determine)
          (NP
            (CONJP (RB:[738..741] not) (RB:[742..746] only))
            (NP
              (NP (DT:[747..750] the) (NN:[751..759] presence))
              (PP (IN:[760..762] of)
                (NP (DT:[763..764] a) (NN:[765..773] mutation))))
            (,:[773..774] ,)
            (CONJP (CC:[776..779] but) (RB:[780..784] also))
            (NP
              (NP (DT:[785..788] the) (JJ:[789..799] mutational)
                  (NN:[800..804] type))
              (PP (IN:[805..807] of)
                (NP (NN:[808..813] K-ras)))
              (PP-LOC (IN:[814..816] at)
                (NP (NN:[817..822] codon) (CD:[823..825] 12))))))))
    (.:[825..826] .)))

;sentence 6 Span:827..909
;The minimal ratio of mutant  DNA detectable by the HPA was 5-10% of the total
;DNA.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[827..830] The) (JJ:[831..838] minimal) (NN:[839..844] ratio))
      (PP (IN:[845..847] of)
        (NP
          (NP (JJ:[848..854] mutant) (NN:[856..859] DNA))
          (ADJP (JJ:[860..870] detectable)
            (PP (IN:[871..873] by)
              (NP (DT:[874..877] the) (NN:[878..881] HPA)))))))
    (VP (VBD:[882..885] was)
      (NP-PRD
        (NP
          (QP (CD:[886..887] 5) (HYPH:[887..888] -) (CD:[888..890] 10))
          (NN:[890..891] %))
        (PP (IN:[892..894] of)
          (NP (DT:[895..898] the) (JJ:[899..904] total) (NN:[905..908] DNA)))))
    (.:[908..909] .)))

;sentence 7 Span:910..1054
;PPJ was collected through  a cannula under duodenal fiberscope control from
;20 patients with PC and 20  patients with chronic pancreatitis (CP).
;[1003..1005]:malignancy:"PC"
(SENT
  (S
    (NP-SBJ-1 (NN:[910..913] PPJ))
    (VP (VBD:[914..917] was)
      (VP (VBN:[918..927] collected)
        (NP-1 (-NONE-:[927..927] *))
        (PP (IN:[928..935] through)
          (NP
            (NP (DT:[937..938] a) (NN:[939..946] cannula))
            (PP (IN:[947..952] under)
              (NP (JJ:[953..961] duodenal) (NN:[962..972] fiberscope)
                  (NN:[973..980] control)))))
        (PP (IN:[981..985] from)
          (NP
            (NP
              (NP (CD:[986..988] 20) (NNS:[989..997] patients))
              (PP (IN:[998..1002] with)
                (NP (NN:[1003..1005] PC))))
            (CC:[1006..1009] and)
            (NP
              (NP (CD:[1010..1012] 20) (NNS:[1014..1022] patients))
              (PP (IN:[1023..1027] with)
                (NP
                  (NP (JJ:[1028..1035] chronic) (NN:[1036..1048] pancreatitis))
                  (NP (-LRB-:[1049..1050] -LRB-) (NN:[1050..1052] CP)
                      (-RRB-:[1052..1053] -RRB-)))))))))
    (.:[1053..1054] .)))

;sentence 8 Span:1055..1216
;Analysis of PPJ by the HPA revealed  that the incidence of K-ras point
;mutations at codon 12 was 55% (11/20) in  patients with PC and 0% (0/20) in
;those with CP.
;[1114..1119]:gene-rna:"K-ras"
;[1120..1135]:variation-type:"point mutations"
;[1139..1147]:variation-location:"codon 12"
;[1182..1184]:malignancy:"PC"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1055..1063] Analysis))
      (PP (IN:[1064..1066] of)
        (NP (NN:[1067..1070] PPJ)))
      (PP (IN:[1071..1073] by)
        (NP (DT:[1074..1077] the) (NN:[1078..1081] HPA))))
    (VP (VBD:[1082..1090] revealed)
      (SBAR (IN:[1092..1096] that)
        (S
          (NP-SBJ
            (NP (DT:[1097..1100] the) (NN:[1101..1110] incidence))
            (PP (IN:[1111..1113] of)
              (NP (NN:[1114..1119] K-ras)
                 (NN:[1120..1125] point) (NNS:[1126..1135] mutations)))
            (PP-LOC (IN:[1136..1138] at)
              (NP (NN:[1139..1144] codon) (CD:[1145..1147] 12))))
          (VP
            (VP (VBD:[1148..1151] was)
              (NP-PRD=1 (CD:[1152..1154] 55) (NN:[1154..1155] %)
                (PRN (-LRB-:[1156..1157] -LRB-)
                  (NP
                    (NP (CD:[1157..1159] 11))
                    (PP (SYM:[1159..1160] /)
                      (NP (CD:[1160..1162] 20))))
                  (-RRB-:[1162..1163] -RRB-)))
              (PP-LOC=2 (IN:[1164..1166] in)
                (NP
                  (NP (NNS:[1168..1176] patients))
                  (PP (IN:[1177..1181] with)
                    (NP (NN:[1182..1184] PC))))))
            (CC:[1185..1188] and)
            (VP
              (NP-PRD=1 (CD:[1189..1190] 0) (NN:[1190..1191] %)
                (PRN (-LRB-:[1192..1193] -LRB-)
                  (NP
                    (NP (CD:[1193..1194] 0))
                    (PP (SYM:[1194..1195] /)
                      (PP (CD:[1195..1197] 20))))
                  (-RRB-:[1197..1198] -RRB-)))
              (PP-LOC=2 (IN:[1199..1201] in)
                (NP
                  (NP (DT:[1202..1207] those))
                  (PP (IN:[1208..1212] with)
                    (NP (NN:[1213..1215] CP))))))))))
    (.:[1215..1216] .)))

;sentence 9 Span:1217..1363
;Mutational types of K-ras at  codon 12 in PC were aspartic acid (Asp) in nine
;cases, both Asp and cysteine in  one case, and arginine in one case.
;[1237..1242]:gene-rna:"K-ras"
;[1247..1255]:variation-location:"codon 12"
;[1259..1261]:malignancy:"PC"
;[1267..1280]:variation-state-generic:"aspartic acid"
;[1282..1285]:variation-state-generic:"Asp"
;[1307..1310]:variation-state-generic:"Asp"
;[1315..1323]:variation-state-generic:"cysteine"
;[1342..1350]:variation-state-generic:"arginine"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1217..1227] Mutational) (NNS:[1228..1233] types))
      (PP (IN:[1234..1236] of)
        (NP (NN:[1237..1242] K-ras)))
      (PP-LOC (IN:[1243..1245] at)
        (NP (NN:[1247..1252] codon) (CD:[1253..1255] 12)))
      (PP (IN:[1256..1258] in)
        (NP (NN:[1259..1261] PC))))
    (VP
      (VP (VBD:[1262..1266] were)
        (NP-PRD=1
          (NP (JJ:[1267..1275] aspartic) (NN:[1276..1280] acid))
          (NP (-LRB-:[1281..1282] -LRB-) (NN:[1282..1285] Asp)
              (-RRB-:[1285..1286] -RRB-)))
        (PP=2 (IN:[1287..1289] in)
          (NP (CD:[1290..1294] nine) (NNS:[1295..1300] cases))))
      (,:[1300..1301] ,)
      (VP
        (NP-PRD=1 (CC:[1302..1306] both) (NN:[1307..1310] Asp)
                  (CC:[1311..1314] and) (NN:[1315..1323] cysteine))
        (PP=2 (IN:[1324..1326] in)
          (NP (CD:[1328..1331] one) (NN:[1332..1336] case))))
      (,:[1336..1337] ,) (CC:[1338..1341] and)
      (VP
        (NP-PRD=1 (NN:[1342..1350] arginine))
        (PP=2 (IN:[1351..1353] in)
          (NP (CD:[1354..1357] one) (NN:[1358..1362] case)))))
    (.:[1362..1363] .)))

;sentence 10 Span:1364..1583
;Analysis of K-ras point mutations at codon  12 in PPJ using the HPA method
;seems promising as a new genetic test for the  diagnosis of PC, because the
;HPA method is simple, and can easily determine the  mutational type.
;[1376..1381]:gene-rna:"K-ras"
;[1382..1397]:variation-type:"point mutations"
;[1401..1410]:variation-location:"codon  12"
;[1499..1501]:malignancy:"PC"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1364..1372] Analysis))
        (PP (IN:[1373..1375] of)
          (NP (NN:[1376..1381] K-ras)
             (NN:[1382..1387] point) (NNS:[1388..1397] mutations)))
        (PP (IN:[1398..1400] at)
          (NP (NN:[1401..1406] codon) (CD:[1408..1410] 12)))
        (PP-LOC (IN:[1411..1413] in)
          (NP (NN:[1414..1417] PPJ))))
      (VP (VBG:[1418..1423] using)
        (NP (DT:[1424..1427] the) (NN:[1428..1431] HPA) (NN:[1432..1438] method))))
    (VP (VBZ:[1439..1444] seems)
      (ADJP-PRD (JJ:[1445..1454] promising))
      (PP (IN:[1455..1457] as)
        (NP
          (NP (DT:[1458..1459] a) (JJ:[1460..1463] new)
              (JJ:[1464..1471] genetic) (NN:[1472..1476] test))
          (PP (IN:[1477..1480] for)
            (NP
              (NP (DT:[1481..1484] the) (NN:[1486..1495] diagnosis))
              (PP (IN:[1496..1498] of)
                (NP (NN:[1499..1501] PC)))))))
      (,:[1501..1502] ,)
      (SBAR-PRP (IN:[1503..1510] because)
        (S
          (NP-SBJ (DT:[1511..1514] the) (NN:[1515..1518] HPA)
                  (NN:[1519..1525] method))
          (VP
            (VP (VBZ:[1526..1528] is)
              (ADJP-PRD (JJ:[1529..1535] simple)))
            (,:[1535..1536] ,) (CC:[1537..1540] and)
            (VP (MD:[1541..1544] can)
              (ADVP (RB:[1545..1551] easily))
              (VP (VB:[1552..1561] determine)
                (NP (DT:[1562..1565] the) (JJ:[1567..1577] mutational)
                    (NN:[1578..1582] type))))))))
    (.:[1582..1583] .)))

;section 11 Span:1587..1631
;PMID: 8641983 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1587..1591] PMID) (::[1591..1592] :) (CD:[1593..1600] 8641983)
        (IN:[1601..1602] -LSB-) (NNP:[1602..1608] PubMed) (HYPH:[1609..1610] -)
        (JJ:[1611..1618] indexed) (IN:[1619..1622] for)
        (NNP:[1623..1631] MEDLINE-RSB-)))
